APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1B TRIAL OF ZUMILOKIBART (APG777), ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA AND HIGHLIGHTS 2026 ANTICIPATED MILESTONES AND OUTLOOK

Reuters · 3d ago

Please log in to view news